Carol Tang
Overview
Explore the profile of Carol Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koh L, Pang Q, Novera W, Lim S, Chong Y, Liu J, et al.
Neuro Oncol
. 2024 Oct;
27(2):398-414.
PMID: 39373211
Background: Enhancer of zeste homolog 2 (EZH2), well known for its canonical methyltransferase activity in transcriptional repression in many cancers including glioblastoma (GBM), has an understudied noncanonical function critical for...
2.
Chen Y, Zhang L, Wu X, Sun X, Sundah N, Wong C, et al.
Nat Commun
. 2024 Sep;
15(1):8410.
PMID: 39333499
Conventional magnetic biosensing technologies have reduced analytical capacity for magnetic field dimensionality and require extensive sample processing. To address these challenges, we spatially engineer 3D magnetic response gradients for direct...
3.
Cheng H, Chong Y, Lim E, Lee X, Pang Q, Novera W, et al.
Neuro Oncol
. 2024 Feb;
26(7):1247-1261.
PMID: 38366847
Background: Precision treatment of glioblastoma is increasingly focused on molecular subtyping, with the mesenchymal subtype particularly resistant to temozolomide. Here, we aim to develop a targeted therapy for temozolomide resensitization...
4.
Lam M, Aw J, Tan D, Vijayakumar R, Lim H, Yada S, et al.
Small
. 2023 Aug;
19(52):e2302280.
PMID: 37649234
Glioblastoma (GBM) is the most common primary malignant brain cancer in adults with a dismal prognosis. Temozolomide (TMZ) is the first-in-line chemotherapeutic; however, resistance is frequent and multifactorial. While many...
5.
Zhang Y, Wong C, Lim C, Chen Q, Yu Z, Natalia A, et al.
Nat Commun
. 2023 Jul;
14(1):4278.
PMID: 37460561
Current technologies to subtype glioblastoma (GBM), the most lethal brain tumor, require highly invasive brain biopsies. Here, we develop a dedicated analytical platform to achieve direct and multiplexed profiling of...
6.
Koh L, Novera W, Lim S, Chong Y, Pang Q, Low D, et al.
Pharmacol Res
. 2022 Jun;
182:106308.
PMID: 35714825
This review describes recent technological advances applied to glioblastoma (GBM), a brain tumor with dismal prognosis. International consortial efforts suggest the presence of molecular subtypes within histologically identical GBM tumors....
7.
Monzo P, Crestani M, Chong Y, Ghisleni A, Hennig K, Li Q, et al.
Dev Cell
. 2021 Sep;
56(20):2841-2855.e8.
PMID: 34559979
Glioblastoma are heterogeneous tumors composed of highly invasive and highly proliferative clones. Heterogeneity in invasiveness could emerge from discrete biophysical properties linked to specific molecular expression. We identified clones of...
8.
Xu L, Chen Y, Huang Y, Sandanaraj E, Yu J, Lin R, et al.
Sci Adv
. 2021 May;
7(18).
PMID: 33931443
Molecular profiling of the most aggressive brain tumor glioblastoma (GBM) on the basis of gene expression, DNA methylation, and genomic variations advances both cancer research and clinical diagnosis. The enhancer...
9.
Cheng H, Marvalim C, Zhu P, Law C, Low Z, Chong Y, et al.
Theranostics
. 2021 Apr;
11(11):5127-5142.
PMID: 33859738
Hypoxic microenvironment is a hallmark of solid tumors, especially glioblastoma. The strong reliance of glioma-propagating cells (GPCs) on hypoxia-induced survival advantages is potentially exploitable for drug development. To identify key...
10.
Toh J, Chua L, Ho P, Sandanaraj E, Tang C, Wang H, et al.
Cells
. 2021 Jan;
10(1).
PMID: 33466414
Parkinson's disease (PD) is an age-dependent neurodegenerative condition. Leucine-rich repeat kinase 2 (LRRK2) mutations are the most frequent cause of sporadic and autosomal dominant PD. The exact role of LRRK2...